DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B by Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim, Do-Youn Oh, Hope Uronis, Sun Jin Sym, Mohamad Sonbol, Khaldoun Almhanna, Mohamedtaki A. Tejani, Beodeul Kang, Michael H. Kagey, Melissa Stilian, Calvin Jia, Cynthia A. Sirard, Jaffer A. Ajani, Samuel J. Klempner

Get full text